Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2018’, provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)

- The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects

- The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

AbbVie Inc

Adello Biologics LLC

AlfaSigma SpA

Allergan Plc

Alpha Cancer Technologies Inc

Alteogen Inc

Alvotech Iceland

Amgen Inc

Antibe Therapeutics Inc ...

4D Pharma PLC

AbbVie Inc

Adello Biologics LLC

AlfaSigma SpA

Allergan Plc

Alpha Cancer Technologies Inc

Alteogen Inc

Alvotech Iceland

Amgen Inc

Antibe Therapeutics Inc

Aptevo Therapeutics Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Arven Ilac

Atlantic Bio Sci LLC

Atlantic Healthcare Plc

Avexegen Therapeutics Inc

Bioleaders Corp

BioLingus AG

Biond Biologics Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Celltrion Inc

ChemoCentryx Inc

ChironWells GmbH

Chong Kun Dang Pharmaceutical Corp

Coherus BioSciences Inc

Commence Bio Inc

Concenter BioPharma Silkim Ltd

Daiichi Sankyo Co Ltd

DBV Technologies SA

EA Pharma Co Ltd

Eisai Co Ltd

Eli Lilly and Co

Enterome Bioscience SA

Enzo Biochem Inc

ETX Pharma Inc

Evelo Biosciences Inc

Ferring International Center SA

Fresenius SE & Co KGaA

FYB202 GmbH & Co KG

Galactica Biotech Ltd

Galapagos NV

Genentech Inc

Genor BioPharma Co Ltd

IB Pharmaceuticals Inc

Inception Sciences Inc

InDex Pharmaceuticals Holding AB

Innovation Pharmaceuticals Inc

Innovent Biologics Inc

Inspyr Therapeutics Inc

Johnson & Johnson

Jyant Technologies Inc

Kang Stem Biotech Co Ltd

Kyowa Hakko Kirin Co Ltd

Merck & Co Inc

Mesoblast Ltd

Mitsubishi Tanabe Pharma Corp

Mycenax Biotech Inc

Naia Ltd

Nichi-Iko Pharmaceutical Co Ltd

Nimbus Therapeutics LLC

Oncobiologics Inc

Oncodesign SA

OSE Immunotherapeutics

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Protagonist Therapeutics Inc

Protheragen Inc

Qu Biologics Inc

Re-Pharm Ltd

RedHill Biopharma Ltd

Reliance Life Sciences Pvt Ltd

Sandoz International GmbH

SATT North SAS

Scythian Biosciences Corp

Second Genome Inc

Seres Therapeutics Inc

Shire Plc

Soligenix Inc

Sublimity Therapeutics Ltd

Synedgen Inc

Synlogic Inc

TaiwanJ Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Tetherex Pharmaceuticals Corp

The Cell-Factory BVBA

Theravance Biopharma Inc

Thetis Pharmaceuticals LLC

Tiziana Life Sciences Plc

Ventria Bioscience

Vivelix Pharmaceuticals Ltd

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Crohn’s Disease (Regional Enteritis) – Overview 8

Crohn’s Disease (Regional Enteritis) – Therapeutics Development 9

Crohn ...

Table of Contents

Table of Contents 2

Introduction 7

Crohn’s Disease (Regional Enteritis) – Overview 8

Crohn’s Disease (Regional Enteritis) – Therapeutics Development 9

Crohn’s Disease (Regional Enteritis) – Therapeutics Assessment 29

Crohn’s Disease (Regional Enteritis) – Companies Involved in Therapeutics Development 41

Crohn’s Disease (Regional Enteritis) – Drug Profiles 83

Crohn’s Disease (Regional Enteritis) – Dormant Projects 375

Crohn’s Disease (Regional Enteritis) – Discontinued Products 383

Crohn’s Disease (Regional Enteritis) – Product Development Milestones 385

Appendix 398

List of Tables

List of Tables

Number of Products under Development for Crohn’s Disease (Regional Enteritis), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Tables

Number of Products under Development for Crohn’s Disease (Regional Enteritis), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Products under Development by Companies, H2 2018 (Contd..8), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by 4D Pharma PLC, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by AbbVie Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Adello Biologics LLC, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by AlfaSigma SpA, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Allergan Plc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Alpha Cancer Technologies Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Alteogen Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Alvotech Iceland, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Amgen Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Antibe Therapeutics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Aptevo Therapeutics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Arena Pharmaceuticals Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Artelo Biosciences Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Arven Ilac, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Atlantic Bio Sci LLC, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Atlantic Healthcare Plc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Avexegen Therapeutics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Bioleaders Corp, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by BioLingus AG, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Biond Biologics Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Bristol-Myers Squibb Co, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Celgene Corp, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Celltrion Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by ChemoCentryx Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by ChironWells GmbH, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Coherus BioSciences Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Commence Bio Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Concenter BioPharma Silkim Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by DBV Technologies SA, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by EA Pharma Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Eisai Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Eli Lilly and Co, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Enterome Bioscience SA, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Enzo Biochem Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by ETX Pharma Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Evelo Biosciences Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Ferring International Center SA, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Fresenius SE & Co KGaA, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by FYB202 GmbH & Co KG, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Galactica Biotech Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Galapagos NV, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Genentech Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Genor BioPharma Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by IB Pharmaceuticals Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Inception Sciences Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by InDex Pharmaceuticals Holding AB, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Innovation Pharmaceuticals Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Innovent Biologics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Inspyr Therapeutics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Johnson & Johnson, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Jyant Technologies Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Kang Stem Biotech Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Merck & Co Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Mesoblast Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Mycenax Biotech Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Naia Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Nimbus Therapeutics LLC, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Oncobiologics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Oncodesign SA, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by OSE Immunotherapeutics, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Pfizer Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Protagonist Therapeutics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Protheragen Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Qu Biologics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Re-Pharm Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by RedHill Biopharma Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Reliance Life Sciences Pvt Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Sandoz International GmbH, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by SATT North SAS, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Scythian Biosciences Corp, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Second Genome Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Seres Therapeutics Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Shire Plc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Soligenix Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Sublimity Therapeutics Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Synedgen Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Synlogic Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Tetherex Pharmaceuticals Corp, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by The Cell-Factory BVBA, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Theravance Biopharma Inc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Thetis Pharmaceuticals LLC, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Tiziana Life Sciences Plc, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Ventria Bioscience, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Vivelix Pharmaceuticals Ltd, H2 2018

Crohn’s Disease (Regional Enteritis) – Pipeline by Xbrane Biopharma AB, H2 2018

Crohn’s Disease (Regional Enteritis) – Dormant Projects, H2 2018

Crohn’s Disease (Regional Enteritis) – Dormant Projects, H2 2018 (Contd..1), H2 2018

Crohn’s Disease (Regional Enteritis) – Dormant Projects, H2 2018 (Contd..2), H2 2018

Crohn’s Disease (Regional Enteritis) – Dormant Projects, H2 2018 (Contd..3), H2 2018

Crohn’s Disease (Regional Enteritis) – Dormant Projects, H2 2018 (Contd..4), H2 2018

Crohn’s Disease (Regional Enteritis) – Dormant Projects, H2 2018 (Contd..5), H2 2018

Crohn’s Disease (Regional Enteritis) – Dormant Projects, H2 2018 (Contd..6), H2 2018

Crohn’s Disease (Regional Enteritis) – Dormant Projects, H2 2018 (Contd..7), H2 2018

Crohn’s Disease (Regional Enteritis) – Discontinued Products, H2 2018

Crohn’s Disease (Regional Enteritis) – Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Crohn’s Disease (Regional Enteritis), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Crohn’s Disease (Regional Enteritis), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports